Kaminski; Naftali

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kaminski; Naftali.The latest application filed is for "biomarkers for assessing idiopathic pulmonary fibrosis".

Company Profile

6.9.13

Kaminski; Naftali - New Haven CT
Kaminski; Naftali - Pittsburgh PA
Kaminski; Naftali - Pittsburg PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Biomarkers For Assessing Idiopathic Pulmonary Fibrosis App 20220235417 - Noth; Imre ; et al.	2022-07-28
Biomarkers for assessing idiopathic pulmonary fibrosis Grant 10,961,582 - Noth , et al. March 30, 2	2021-03-30
52-gene signature in peripheral blood identifies a genomic profile associated with increased risk of mortality and poor disease outcomes in idiopathic pulmonary fibrosis Grant 10,896,740 - Kaminski , et al. January 19, 2	2021-01-19
Methods of Treating or Preventing Acute Respiratory Distress Syndrome App 20210008020 - Kaminski; Naftali ; et al.	2021-01-14
Methods of treating or preventing fibrotic lung diseases Grant 10,792,265 - Kaminski , et al. October 6, 2	2020-10-06
Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases App 20200113863 - Kaminski; Naftali ; et al.	2020-04-16
Methods Of Treating Or Preventing Fibrotic Lung Diseases App 20180369179 - KAMINSKI; Naftali ; et al.	2018-12-27
Biomarkers For Assessing Idiopathic Pulmonary Fibrosis App 20180320234 - Noth; Imre ; et al.	2018-11-08
Biomarkers for assessing idiopathic pulmonary fibrosis Grant 10,036,069 - Noth , et al. July 31, 2	2018-07-31
52-gene Signature In Peripheral Blood Identifies A Genomic Profile Associated With Increased Risk Of Mortality And Poor Disease Outcomes In Idiopathic Pulmonary Fibrosis App 20180101642 - Kaminski; Naftali ; et al.	2018-04-12
Methods of treating or preventing fibrotic lung diseases Grant 9,913,819 - Kaminski , et al. March 13, 2	2018-03-13
Novel Methods Of Treating Or Preventing Fibrotic Lung Diseases App 20170105956 - KAMINSKI; Naftali ; et al.	2017-04-20
Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation App 20140335547 - Kaminski; Naftali ; et al.	2014-11-13
Biomarkers For Assessing Idiopathic Pulmonary Fibrosis App 20140323343 - Noth; Imre ; et al.	2014-10-30
Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation Grant 8,846,341 - Kaminski , et al. September 30, 2	2014-09-30
MMP activation peptide detection in biological samples Grant 8,568,996 - Enghild , et al. October 29, 2	2013-10-29
MicroRNAs In Idiopathic Pulmonary Fibrosis App 20120045395 - Kaminski; Naftali ; et al.	2012-02-23
Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation App 20120035067 - Kaminski; Naftali ; et al.	2012-02-09
Mmp Activation Peptide Detection In Biological Samples App 20110212473 - Enghild; Jan Johannes ; et al.	2011-09-01
Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same App 20060003327 - Achiron; Anat ; et al.	2006-01-05

Company Registrations

NCAGE Code	4B2V3	KAMINSKI NAFTALI
CAGE Code	4B2V3	KAMINSKI, NAFTALI
DUNS	619021491	KAMINSKI, NAFTALI

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.